Literature DB >> 18929211

Cutaneous Rosai-Dorfman disease of the forearm: case report.

Christopher A Potts1, Andrew P Bozeman, Anna N Walker, Waldo E Floyd.   

Abstract

Sinus histiocytosis with massive lymphadenopathy, also known as Rosai-Dorfman disease (RDD), is a rare non-neoplastic pathologic condition that frequently pursues a prolonged clinical course marked by exacerbations and remissions. Cutaneous RDD is even less common than cases involving lymph nodes. We present the case of a patient with long-standing Crohn's disease who developed cutaneous RDD in the forearm.

Entities:  

Mesh:

Year:  2008        PMID: 18929211     DOI: 10.1016/j.jhsa.2008.04.003

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  5 in total

1.  Cutaneous rosai-dorfman disease persisting after surgical excision: report of a case treated with acitretin.

Authors:  Katherine Fening; Mark Bechtel; Sara Peters; Matthew Zirwas; Kamruz Darabi
Journal:  J Clin Aesthet Dermatol       Date:  2010-09

2.  Soft Tissue Rosai-Dorfman Disease: Case report.

Authors:  Rubyath C Rajib; Rajasekharan Pillai; Ibrahim A Sulaiman; Ibrahim Al-Haddabi
Journal:  Sultan Qaboos Univ Med J       Date:  2018-01-10

3.  Possible association of cutaneous Rosai-Dorfman disease and chronic Crohn disease: a case series report.

Authors:  Katrin A Salva; Melissa Stenstrom; Jonith Y Breadon; Paul Blair Odland; Daniel Bennett; Jack Longley; Gary S Wood
Journal:  JAMA Dermatol       Date:  2014-02       Impact factor: 10.282

4.  Extranodal Rosai-Dorfman disease: a rare soft tissue neoplasm masquerading as a sarcoma.

Authors:  Mahathi Komaragiri; Lauren S Sparber; Maria Laureana Santos-Zabala; Michael Dardik; Ronald S Chamberlain
Journal:  World J Surg Oncol       Date:  2013-03-09       Impact factor: 2.754

5.  Purely cutaneous rosai-dorfman disease with immunohistochemistry.

Authors:  Uzma Farooq; Anna H Chacon; Vladimir Vincek; George W Elgart
Journal:  Indian J Dermatol       Date:  2013-11       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.